Development of a New Composite Bone Cement as a Bone Substitute for Vertebroplasty
A new composite bone cement designated ‘G2B1’ was developed for percutaneous transpedicular vertebroplasty. G2B1 contains beta tricalcium phosphate particles and methylmethacrylate –methylacrylate copolymer as the powder components, and methylmethacrylate, urethane dimethacrylate, and tetrahydrofurfuryl methacrylate as the liquid components. Osteoconductivity and histological changes with time were evaluated using scanning electron microscopy, contact microradiography, and Giemsa surface staining 4, 8, 12, 26, and 52 weeks after implantation into rat tibiae. To evaluate osteoconductivity, affinity indices (%) were calculated. Scanning electron microscopy and contact microradiography revealed that bone contact with G2B1 was attained within 4 weeks (affinity index: 50.2 ± 11.8 at 4 weeks) and at most of the margin within 26 weeks (affinity index: 87.4 ± 7.2 at 26 weeks). Giemsa surface staining showed that there was almost no inflammatory reaction around the G2B1. These results indicate that G2B1 is a biocompatible and highly osteoconductive bone cement.
Takashi Nakamura, Kimihiro Yamashita and Masashi Neo
K. Goto et al., "Development of a New Composite Bone Cement as a Bone Substitute for Vertebroplasty ", Key Engineering Materials, Vols. 309-311, pp. 805-808, 2006